Literature DB >> 18644953

Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Adam Belley1, Eve Neesham-Grenon, Francis F Arhin, Geoffrey A McKay, Thomas R Parr, Gregory Moeck.   

Abstract

Oritavancin is a semisynthetic lipoglycopeptide in clinical development for serious gram-positive infections. This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18644953      PMCID： PMC2565878          DOI： 10.1128/AAC.00361-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins.

Authors:  Yan-Qiong Xiong; Arnold S Bayer; Michael R Yeaman
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

Review 2.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 4.  Mechanism of action of oritavancin and related glycopeptide antibiotics.

Authors:  Norris E Allen; Thalia I Nicas
Journal:  FEMS Microbiol Rev       Date:  2003-01       Impact factor: 16.408

Review 5.  The importance of bactericidal drugs: future directions in infectious disease.

Authors:  Robert W Finberg; Robert C Moellering; Francis P Tally; William A Craig; George A Pankey; E Patchen Dellinger; Michael A West; Manjari Joshi; Peter K Linden; Ken V Rolston; John C Rotschafer; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2004-10-07       Impact factor: 9.079

Review 6.  Combination antibiotic therapy for infective endocarditis.

Authors:  Thuan Le; Arnold S Bayer
Journal:  Clin Infect Dis       Date:  2003-02-13       Impact factor: 9.079

7.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis.

Authors:  Dragana Drinković; Arthur J Morris; Sudha Pottumarthy; Donald MacCulloch; Teena West
Journal:  J Antimicrob Chemother       Date:  2003-09-30       Impact factor: 5.790

9.  Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone.

Authors:  Byron F Brehm-Stecher; Eric A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.

Authors:  C Chuard; M Herrmann; P Vaudaux; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191
View more
  25 in total

1.  Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Authors:  Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 2.  Oritavancin: a review in acute bacterial skin and skin structure infections.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

3.  Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Samantha Rosenthal; Arnold G Decano; Aiman Bandali; Denise Lai; Gregory E Malat; Tiffany E Bias
Journal:  P T       Date:  2018-03

4.  Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors:  Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

6.  Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.

Authors:  Adam Belley; David Lalonde Seguin; Francis Arhin; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Authors:  Adam Belley; Eve Neesham-Grenon; Geoffrey McKay; Francis F Arhin; Robert Harris; Terry Beveridge; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

8.  Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.

Authors:  Qun Yan; Melissa J Karau; Yash S Raval; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Antifungal Azoles as Tetracycline Resistance Modifiers in Staphylococcus aureus.

Authors:  Nisha Mahey; Rushikesh Tambat; Dipesh Kumar Verma; Nishtha Chandal; Krishan Gopal Thakur; Hemraj Nandanwar
Journal:  Appl Environ Microbiol       Date:  2021-07-13       Impact factor: 4.792

10.  Multi-target mode of action of silver against Staphylococcus aureus endows it with capability to combat antibiotic resistance.

Authors:  Haibo Wang; Minji Wang; Xiaohan Xu; Peng Gao; Zeling Xu; Qi Zhang; Hongyan Li; Aixin Yan; Richard Yi-Tsun Kao; Hongzhe Sun
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.